Navigation Links
Tianyin Pharmaceutical Co., Inc. Provides Fiscal 2010 Guidance

    CHENGDU, China, June 18/ PRNewswire-Asia-FirstCall/ --

    -- Management expects to report revenues of approximately
       $42 million and net income of approximately $7.5 million for
       the Fiscal Year which ends June 30, 2009.  Fourth quarter
       revenue and net income of approximately $12.4 million and
       $1.8 million, respectively.

    -- Fiscal 2010 Guidance of $59 million in revenue and
       $10.5 million in net income, representing approximately 40%
       and 42% growth over estimated fiscal 2009.

Tianyin Pharmaceutical, Co., Inc., (NYSE AMEX: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced its unaudited, preliminary financial results for the fiscal year ended June 30, 2009, and fiscal 2010 financial guidance. The Company plans to announce the final results and to hold a conference call for 2009 in September.

Fiscal Year 2009 Financial Highlights

Based on preliminary financial data, Tianyin expects to report fiscal 2009 (year ending June 30) revenues of $42 million and net income of at least $7.5 million, representing 25% and 26% year over year growth respectively. Ginko Mihuan is expected to represent approximately 23% of total revenues. This data is subject to normal audit adjustments and therefore may be changed when reported in Tianyin's Annual Report on Form 10-K for the fiscal year ended June 30, 2009.

"We are very pleased with these anticipated results, which have been supported by targeted sales promotion of new and existing products, including Ginko Mihuan, and supported by the further expansion of our sales team and distribution channels." Dr. Jiang, Chairman and CEO of Tianyin commented. "During the 2009 fiscal year, our advertising expense increased 15% to $1.8 million, generating strong brand awareness and creating further demand for our flagship and other proprietary products. In addition, we instituted a cash dividend which enables our shareholders to participate in our profitability each quarter and is something we hope to increase in the future as the Company grows."

"During fiscal 2009, we received approval from the Chinese State Food and Drug Administration (SFDA) for ten new products. These introductions are critical to our growth strategy and our enhanced product portfolio positions us for accelerating revenues during fiscal 2010. We significantly grew the sales of our flagship Gingko Mihuan through successful tenders and greatly expanded the number of distributors actively marketing this product. We also completed the build-out of our new production facility and are currently initiating GMP certification process. The recent passage of the Healthcare Reform Act was a significant milestone and will culminate into approximately $126 Billion being spent by the government during the next 3 years to bring universal healthcare to all Chinese citizens. As a further component, the central government openly stated its support for Traditional Chinese Medicine (TCM), which will receive additional incentives and funding; this is a policy that we believe will have significant positive implications for our industry," Dr. Jiang stated.

Fiscal Year 2010 Financial Guidance

For fiscal year 2010 which ends June 30, 2010, Tianyin forecasts that revenues will exceed $59 million with net income at least $10.5 million, representing approximately 40% and 42% growth compared to fiscal 2009 forecasts. Management anticipates that approximately $7 million, or 12% of total revenues will result from products which were launched during fiscal 2009, while it is anticipated that sales of the Company's flagship product, Ginko Mihuan, will grow by approximately 80% to $20 million for the year. Net income forecasted does not include non-cash expenses associated with stock compensation plans or future interest expense. This guidance does not include any contribution from potential future acquisitions and management will continue to evaluate its business outlook as necessary and communicate any changes on a quarterly basis or when appropriate. At the time of this release, the Company does not have any formal agreements nor is it involved in any definitive discussions regarding potential acquisitions.

Growth will be supported by a number of initiatives, including: 1) Receiving GMP certification for Tianyin's new production facility will increase its capacity for solid dosage by 300% and enable future growth for 20 of its products; 2) this new facility will enable the company to initiate a wholesale component to its business focused exclusively on distributing higher margin, specialty products for other pharmaceutical manufactures through the existing sales force and distribution channels; 3) the new Healthcare Reform Act is expected to increase the demand for approximately 20 of the total 22 drugs Tianyin currently has listed in the reimbursement catalog; 4) expanding its targeted marketing strategy, including multi-media and television advertising, to further brand and promote higher gross-profit-margin products, such as Ginkgo Mihuan Oral Liquid and Xuelian Cangcao; 5) expand collaboration with universities and research organizations to complement Tianyin's internal drug development efforts and continue introducing new products to the market; and, 6) continue looking for complementary acquisitions primarily focused on existing product lines which would increase the depth and breadth of the existing portfolio.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     Tel:   +86-158-2122-5642

     HC International, Inc.
     Matt Hayden
     Tel:   +1-561-245-5155

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: